Recent developments in Paget's disease

Advanced Studies in Medicine

Volumn 3, Issue 5, 2003, Pages 286-292

  Roodman, G David ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D;

BONE PAIN; CELL ACTIVITY; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DRUG RESPONSE; ENZYME ASSAY; EPIDEMIOLOGICAL DATA; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; MEASLES; MEASLES VIRUS; NAUSEA; OSTEOCLAST; OSTEOLYSIS; OSTEOMALACIA; PAGET BONE DISEASE; RADIODIAGNOSIS; REVIEW; SKELETON MALFORMATION; SKIN MANIFESTATION; TREATMENT OUTCOME; VIRUS GENE;

EID: 0037838480     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Delmas PD, Meunier PJ. Drug therapy: the management of Paget's disease of the bone. N Engl J Med. 1997;336:558-566.
2. Meunier PJ, Salson C, Mathieu L, et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop. 1987;217:37-44.
3. Ooi CG, Fraser WD. Paget's disease of bone. Postgrad Med J. 1997;73:69-74.
4. Roodman GD. Paget's disease and osteoclast biology. Bone. 1996;19:209-212.
5. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, Garcia-Sagredo JM, Lopez-Abente G. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res. 1995;10:663-670.
6. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990;8:87-96.
7. Alvarez L, Peris P, Pons F, et al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis Rheum. 1997;40:461-468.
8. Hosking DJ. Paget's disease of bone. Br Med J (Clin Res Ed). 1981;283:686-688.
9. Rebel A, Basle M, Pouplard A, Malkani K, Filmon R, Lepatezour A. Towards a viral etiology for Paget's disease of bone. Metab Bone Dis Relat Res. 1981;3:235-238.
10. Abe S, Ohno T, Park P, Higaki S, Unno K, Tateishi A. Viral behavior of paracrystalline inclusions in osteoclasts of Paget's disease of bone. Ultrastruct Pathol. 1995;19:455-461.
11. Mills BG, Singer FR, Weiner LP, Suffin SC, Stabile E, Holst P. Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin Orthop. 1984;183:303-311.
12. Mills BG, Singer FR. Critical evaluation of viral antigen data in Paget's disease of bone. Clin Orthop. 1987;217:16-25.
13. Basle MF, Russell WC, Goswami KK, et al. Paramyxovirus antigens in osteoclasts from Paget's bone tissue detected by monoclonal antibodies. J Gen Virol. 1985;66:2103-2110.
14. Mills BG, Frausto A, Singer FR, Ohsaki Y, Demulder A, Roodman GD. Multinucleated cells formed in vitro from Paget's bone marrow express viral antigens. Bone. 1994;15:443-448.
15. Friedrichs W, Reddy SV, Bruder JM, et al. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res. 2002;17:145-157.
16. Reddy SV, Singer FR, Roodman GD. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab. 1995;80:2108-2111.
17. Birch MA, Taylor W, Fraser WD, Ralston SH, Hart CA, Gallagher JA. Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone. J Bone Miner Res. 1994;9:11-16.
18. Helfrich MH, Hobson RP, Grabowski PS, et al. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res. 2000;15:2315-2329.
19. Kurihara N, Reddy SV, Menaa C, Anderson D, Roodman GD. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest. 2000;105:607-614.
20. Reddy SV, Kurihara N, Menaa C, et al. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology. 2001;142:2898-2905.
21. Brock TD, ed. Milestones in Microbiology. 2nd ed. Washington, DC: ASM Press; 1998.
22. Anderson DC, O'Driscoll JB. Dogs and Paget's disease. Lancet. 1986;1:41.
23. Gordon MT, Anderson DC, Sharpe PT. Canine distemper virus localised in bone cells of patients with Paget's disease. Bone. 1991;12:195-201.
24. Mee AP, Dixon JA, Hoyland JA, Davies M, Selby PL, Mawer EB. Detection of canine distemper virus in 100% of Paget's disease samples by in situ reverse transcriptase-polymerase chain reaction. Bone. 1998;23:171-175.
25. Gascon GG. Subacute sclerosing panencephalitis. Semin Pediatr Neurol. 1996;3:260-269.
26. Kai C, Yamanouchi K, Sakata H, Miyashita N, Takahashi H, Kobune F. Nucleotide sequences of the M gene of prevailing wild measles viruses and a comparison with subacute sclerosing panencephalitis virus. Virus Genes. 1996;12:85-87.
27. Marschall M, Schuler A, Meier-Ewert H. Influenza C virus RNA is uniquely stabilized in a steady state during primary and secondary persistent infections. J Gen Virol. 1996;77:681-686.
28. Lin F, Mackay DK, Knowles NJ. The persistence of swine vesicular disease virus infection in pigs. Epidemiol Infect. 1998;121:459-472.
29. Reddy SV, Menaa C, Singer FR, et al. Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Exp Hematol. 1999;27:1528-1532.
30. Cody JD, Singer FR, Roodman GD, et al. Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet. 1997;61:1117-1122.
31. Good D, Busfield F, Duffy D, et al. Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree. J Bone Miner Res. 2001;16:33-38.
32. Laurin N, Brown JP, Lemainque A, et al. Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet. 2001;69:528-543.
33. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70:1582-1588.
34. Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24:45-48.
35. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. 4th ed. San Diego, Calif: Academic Press; 2000.
36. Ankrom MA, Shapiro JR. Paget's disease of bone (osteitis deformans). J Am Geriatr Soc. 1998;46:1025-1033.
37. Paget J. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans. 1877;60:37-64.
38. Wood R, Donaghy M, Dundas S. Monitoring patients in the community with suspected Escherichia coli O157 infection during a large outbreak in Scotland in 1996. Epidemiol Infect. 2001;127:413-420.
39. Dundas S, Todd WTA, Stewart AI, Murdoch PS, Chaudhuri AKR, Hutchinson SJ. The Central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis. 2002;33:923-931.
40. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930-1936.
41. Novicki TJ, Daly JA, Mottice SL, Carroll KC. Comparison of sorbitol MacConkey agar and two-step method which utilizes enzyme-linked immunosorbent assay toxin testing and a chromogenic agar to detect and isolate enterohemorrhagic Escherichia coli. J Clin Microbiol. 2000;38:547-551.
42. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DWK. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis. 2000;181:664-670.
43. Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis. 2000;6:458-465.
44. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis. JAMA. 2002;288:996-1001.
45. Molbak K, Mead PS, Griffin PM. Antimicrobial therapy in patients with Escherichia coli O157:H7 infection. JAMA. 2002;288:1014-1016.
46. Guerrant RL, Van Gilder R, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32:331-350.
47. Preliminary FoodNet data on the incidence of food-borne illnesses: selected sites, United States. MMWR Morb Mortal Wkl Rep. 2003;51:325-329.
48. Nishikawa K, Matsuoka K, Kita E, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc Natl Acad Sci. 2002;99:7769-7774.
49. Donnelly JJ, Rappuoli R. Blocking bacterial enterotoxins. Nat Med. 2000;6:257-258.
50. Suzaki Y, Ami Y, Nagata N, et al. Protection of monkeys against Shiga toxin induced by Shiga toxin-liposome conjugates. Int Arch Allergy Immunol. 2002;127:294-298.
51. Mukherjee J, Chios K, Fishwild D, et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun. 2002;70:612-619.